Home
Conditions
Hematologic Diseases

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,354 public trials 2,837 recruiting studies

Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT06034002

Conditions: Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +8 more
Locations: City of Hope Medical Center Duarte, California, United States

Stanford Cancer Institute Palo Alto, California, United States

University of Miami Health System Miami, Florida, United States

The University of Kansas Cancer Center Westwood, Kansas, United States

View all 13 locations

View Trial Details

Recruiting

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

NCT03893045

Conditions: Anemia, Anemia, Hypochromic, Anemia, Iron-Deficiency, +7 more
Locations: Arkansas Children's Hospital Little Rock, Arkansas, United States

University of Florida Gainesville, Florida, United States

Optimus U Corporation Miami, Florida, United States

Biomedical Research LLC Miami, Florida, United States

View all 15 locations

View Trial Details

Recruiting

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

NCT04797767

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Hematologic Diseases, +26 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850

Conditions: Anemia, Anemia, Hypochromic, Anemia, Iron-Deficiency, +19 more
Locations: Memorial Healthcare System Hollywood, Florida, United States

Wayne State University Detroit, Michigan, United States

Children's Mercy Hospital Kansas City, Missouri, United States

The Feinstein Institute Medical Research Organization of Northwell Health, Inc. Lake Success, New York, United States

View all 21 locations

View Trial Details

Recruiting

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

NCT07224100

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Hematologic Diseases, +11 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

NCT06424340

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +4 more
Locations: Leiden University Medical Center Leiden, Netherlands

View Trial Details

Recruiting

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

NCT00816114

Conditions: Bone Marrow Diseases, Chronic Disease, Chronic Myelogenous Leukemia, +11 more
Locations: University of Texas MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy

NCT06439199

Conditions: Acute Myeloid Leukemia, Bone Marrow Diseases, Chronic Disease, +14 more
Locations: Nantes University Hospital Nantes, Loire-Atlantique, France

View Trial Details

Recruiting

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

NCT05170412

Conditions: Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +7 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT04140487

Conditions: Bone Marrow Diseases, Chronic Disease, Disease Attributes, +17 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Hematologic Diseases

Hematologic Diseases trial results

Related conditions